(Q38763559)

6 September 2017

title

Current and emerging therapeutic targets for IBD. (English)

1 reference

6 September 2017

Markus F Neurath

1

1 reference

6 September 2017

language of work or name

English

0 references

publication date

1 February 2017

1 reference

Nature Reviews Gastroenterology & Hepatology

6 September 2017

published in

1 reference

6 September 2017

volume

14

1 reference

6 September 2017

issue

5

1 reference

6 September 2017

page(s)

269-278

1 reference

https://scigraph.springernature.com/pub.10.1038/nrgastro.2016.208

6 September 2017

exact match

0 references

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

5-aminosalicylates and colorectal cancer: preventive role in chronic inflammatory bowel disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Designer Thiopurine-analogues for Optimised Immunosuppression in Inflammatory Bowel Diseases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Colonic microbiota can promote rapid local improvement of murine colitis by thioguanine independently of T lymphocytes and host metabolism.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Infliximab, azathioprine, or combination therapy for Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Methotrexate for the Treatment of Crohn's Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Cyclosporine A regulates pro-inflammatory cytokine production in ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Mechanisms of action of cyclosporine.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Methotrexate induces poly(ADP-ribose) polymerase-dependent, caspase 3-independent apoptosis in subsets of proliferating CD4+ T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

6-Mercaptopurine reduces macrophage activation and gut epithelium proliferation through inhibition of GTPase Rac1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Predicting the response to infliximab from trough serum levels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Adalimumab induces deep remission in patients with Crohn's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Cytokines in inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Infliximab Therapy Inhibits Inflammation-Induced Angiogenesis in the Mucosa of Patients With Crohnʼs Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Caspase-8 regulates TNF-α-induced epithelial necroptosis and terminal ileitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Differential effects of TNF (TNFSF2) and IFN-γ on intestinal epithelial cell morphogenesis and barrier function in three-dimensional culture

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Effect of the anti-tumor necrosis factor-alpha antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Anti-tumor necrosis factor-α antibodies induce regulatory macrophages in an Fc region-dependent manner

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Natalizumab for active Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Vedolizumab as induction and maintenance therapy for ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Vedolizumab as induction and maintenance therapy for Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Blockade of αEβ7 integrin suppresses accumulation of CD8+ and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Diagnosis and management of intestinal Behçet's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Matrix metalloproteinase 9-induced increase in intestinal epithelial tight junction permeability contributes to the severity of experimental DSS colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Matrix metalloproteinase-9: its interplay with angiogenic factors in inflammatory bowel diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Pivotal Role of Carbohydrate Sulfotransferase 15 in Fibrosis and Mucosal Healing in Mouse Colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Phase 1 Clinical Study of siRNA Targeting Carbohydrate Sulphotransferase 15 in Crohn's Disease Patients with Active Mucosal Lesions.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

IL-17A directly inhibits TH1 cells and thereby suppresses development of intestinal inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

IL-6 is required for the development of Th1 cell-mediated murine colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Blockade of interleukin 6 trans signaling suppresses T-cell resistanceagainst apoptosis in chronic intestinal inflammation: Evidence in Crohn diseaseand experimental colitis in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

IL-23: a master regulator in Crohn disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Antibodies to interleukin 12 abrogate established experimental colitis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Targeting IL-23 and Th17-cytokines in inflammatory bowel diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

IL-23R+ innate lymphoid cells induce colitis via interleukin-22-dependent mechanism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Ustekinumab induction and maintenance therapy in refractory Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Anti-interleukin-12 antibody for active Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

31 March 2020

Late-breaking abstracts

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Update on Janus kinase antagonists in inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

TH9 cells that express the transcription factor PU.1 drive T cell–mediated colitis via IL-9 receptor signaling in intestinal epithelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Upregulated IL-7 receptor α expression on colitogenic memory CD4+ T cells may participate in the development and persistence of chronic colitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Inhibitors of phosphodiesterase 4 (PDE 4): A new therapeutic option in the treatment of psoriasis vulgaris and psoriatic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Rectal Delivery of a DNAzyme That Specifically Blocks the Transcription Factor GATA3 and Reduces Colitis in Mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Transient inhibition of ROR-γt therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

F1C fimbriae play an important role in biofilm formation and intestinal colonization by the Escherichia coli commensal strain Nissle 1917.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Mucosal barrier in ulcerative colitis and Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Phosphatidylcholine (lecithin) and the mucus layer: Evidence of therapeutic efficacy in ulcerative colitis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

A pathogenic role for T cell-derived IL-22BP in inflammatory bowel disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Toll-like receptor-7 ligand Imiquimod induces type I interferon and antimicrobial peptides to ameliorate dextran sodium sulfate-induced acute colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Transforming growth factor beta induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

TGF-beta1 and Smad7 in the regulation of IBD.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Review article: the efficacy of infliximab in Crohn's disease--healing of fistulae

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells Promote Healing of Refractory Perianal Fistulas in Patients With Crohn's Disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Autologous expanded adipose-derived stem cells for the treatment of complex cryptoglandular perianal fistulas: a phase III randomized clinical trial (FATT 1: fistula Advanced Therapy Trial 1) and long-term evaluation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Ex vivo immunosuppressive effects of mesenchymal stem cells on Crohn's disease mucosal T cells are largely dependent on indoleamine 2,3-dioxygenase activity and cell-cell contact.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Treatment of Crohn's-Related Rectovaginal Fistula With Allogeneic Expanded-Adipose Derived Stem Cells: A Phase I-IIa Clinical Trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

How cytokine networks fuel inflammation: Toward a cytokine-based disease taxonomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

New therapies for inflammatory bowel disease: from the bench to the bedside

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Mucosal healing in inflammatory bowel diseases: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.208

The S1P receptor modulator FTY720 prevents the development of experimental colitis in mice

31 March 2020

1 reference

12 December 2020

S1pping fire: Sphingosine-1-phosphate signaling as an emerging target in inflammatory bowel disease and colitis-associated cancer

1 reference

12 December 2020

S1P signaling: new therapies and opportunities

1 reference

12 December 2020

Vedolizumab for induction and maintenance of remission in ulcerative colitis

1 reference

12 December 2020

Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution

1 reference

12 December 2020

Aminosalicylates for induction of remission or response in Crohn's disease

1 reference

12 December 2020

Budesonide for induction of remission in Crohn's disease

1 reference

12 December 2020

Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease

1 reference

12 December 2020

Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells

1 reference

12 December 2020

Systematic review and meta-analysis of third-line salvage therapy with infliximab or cyclosporine in severe ulcerative colitis

1 reference

12 December 2020

10.1038/NRGASTRO.2016.208

Identifiers

DOI

1 reference

Dimensions Publication ID

6 September 2017

1083399953

0 references

1 reference